The funding deal is a vote of confidence in the sales potential of multiple prospects in late-stage development — one of ...
The U.S. Food and Drug Administration has approved Lumvoa (veligrotug-vvze) for the treatment of thyroid eye disease (TED).
Khanani, MD, MA, FASRS, founded Clinical Trials at the Summit (CTS) 6 years ago, the vision was to bring all stakeholders in retinal drug development together under one roof. At this year's meeting, ...
The FDA granted regenerative medicine advanced therapy designation to EO2002 for the treatment of corneal edema secondary to ...
In today's Pharmaceutical Executive Daily, Vertex Pharmaceuticals announces a $10 billion acquisition of Crinetics ...
MeiraGTx has secured an investment of up to $400 million from Oberland Capital to help get its late-stage gene therapies | As ...
Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, and Nanoscope Therapeutics, a biotechnology company committed to commercializing novel, disease ...
Houston biopharma company CoRegen said it has received US Food and Drug Administration clearance to begin a Phase I/II trial of CRG-150, an adoptive cell therapy targeting steroid receptor coactivator ...
Catalent & Nanoscope Therapeutics Expand Partnership to Support Late-Phase Development and Commercial Supply of Lead Optogenetic Gene Therapy, MCO-010 ...
Inherited retinal degenerations are a diverse group of genetic disorders that result in progressive vision loss. Advances in ...
Casgevy is the first gene therapy approved for sickle cell disease and transfusion-dependent beta-thalassemia in patients aged 2 and older.
Hiroshima University researchers have demonstrated a proof of concept for the mass production of genome-edited T cells that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results